Concepts (73)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiotherapy, Intensity-Modulated | 1 | 2014 | 34 | 0.450 |
Why?
|
Patient Positioning | 1 | 2014 | 41 | 0.450 |
Why?
|
Breast Neoplasms | 4 | 2014 | 1129 | 0.430 |
Why?
|
Mastectomy, Segmental | 2 | 2014 | 45 | 0.220 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 55 | 0.210 |
Why?
|
Organs at Risk | 1 | 2014 | 5 | 0.120 |
Why?
|
Prone Position | 1 | 2014 | 27 | 0.110 |
Why?
|
Carcinoma, Lobular | 1 | 2014 | 23 | 0.110 |
Why?
|
Neoplasms, Second Primary | 1 | 2014 | 41 | 0.110 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 45 | 0.110 |
Why?
|
Ovarian Follicle | 1 | 2014 | 39 | 0.110 |
Why?
|
Radiation Injuries | 1 | 2014 | 56 | 0.110 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2013 | 77 | 0.110 |
Why?
|
Neoadjuvant Therapy | 1 | 2013 | 70 | 0.110 |
Why?
|
Anti-Mullerian Hormone | 1 | 2014 | 62 | 0.110 |
Why?
|
Thymidine Phosphorylase | 1 | 2012 | 4 | 0.110 |
Why?
|
Neoplasm Staging | 1 | 2014 | 454 | 0.100 |
Why?
|
Deoxycytidine | 1 | 2012 | 39 | 0.100 |
Why?
|
Fluorouracil | 1 | 2012 | 54 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 38 | 0.100 |
Why?
|
Breast | 1 | 2014 | 173 | 0.100 |
Why?
|
X-Ray Intensifying Screens | 1 | 2012 | 8 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2014 | 527 | 0.100 |
Why?
|
Radiotherapy, Conformal | 1 | 2012 | 20 | 0.100 |
Why?
|
Radiometry | 1 | 2012 | 34 | 0.100 |
Why?
|
Radiotherapy Dosage | 1 | 2012 | 79 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2013 | 301 | 0.100 |
Why?
|
Biomarkers, Tumor | 1 | 2014 | 453 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 404 | 0.090 |
Why?
|
Lung | 1 | 2014 | 833 | 0.080 |
Why?
|
Cerebral Veins | 1 | 2009 | 36 | 0.080 |
Why?
|
Follow-Up Studies | 1 | 2014 | 2327 | 0.080 |
Why?
|
Brain Neoplasms | 1 | 2012 | 306 | 0.080 |
Why?
|
Prospective Studies | 1 | 2014 | 3095 | 0.070 |
Why?
|
Time Factors | 1 | 2014 | 3573 | 0.070 |
Why?
|
Multiple Sclerosis | 1 | 2009 | 208 | 0.070 |
Why?
|
Gene Products, tat | 1 | 2005 | 14 | 0.060 |
Why?
|
Cysteine | 1 | 2005 | 108 | 0.060 |
Why?
|
Arginine | 1 | 2005 | 113 | 0.060 |
Why?
|
Peptide Fragments | 1 | 2005 | 349 | 0.060 |
Why?
|
Female | 6 | 2014 | 30883 | 0.050 |
Why?
|
HIV-1 | 1 | 2005 | 705 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2009 | 2037 | 0.040 |
Why?
|
Middle Aged | 2 | 2014 | 16248 | 0.040 |
Why?
|
Humans | 7 | 2014 | 59419 | 0.040 |
Why?
|
Prognosis | 2 | 2013 | 1572 | 0.040 |
Why?
|
HIV Infections | 1 | 2005 | 920 | 0.040 |
Why?
|
Inhibins | 1 | 2014 | 46 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 1 | 2014 | 78 | 0.030 |
Why?
|
Capecitabine | 1 | 2012 | 10 | 0.030 |
Why?
|
Estradiol | 1 | 2014 | 242 | 0.030 |
Why?
|
Radiography | 1 | 2012 | 506 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 645 | 0.020 |
Why?
|
Biomarkers | 1 | 2012 | 1199 | 0.020 |
Why?
|
Infant | 1 | 2012 | 1523 | 0.020 |
Why?
|
Child, Preschool | 1 | 2012 | 1838 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2009 | 1094 | 0.020 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2005 | 13 | 0.020 |
Why?
|
Receptors, CCR5 | 1 | 2005 | 57 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2005 | 353 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2005 | 138 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2009 | 1548 | 0.010 |
Why?
|
Molecular Structure | 1 | 2005 | 376 | 0.010 |
Why?
|
DNA Replication | 1 | 2005 | 229 | 0.010 |
Why?
|
NF-kappa B | 1 | 2005 | 461 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 692 | 0.010 |
Why?
|
Child | 1 | 2012 | 4305 | 0.010 |
Why?
|
Young Adult | 1 | 2012 | 4314 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2005 | 1373 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 2012 | 0.010 |
Why?
|
Adolescent | 1 | 2012 | 5918 | 0.010 |
Why?
|
Male | 2 | 2012 | 27545 | 0.010 |
Why?
|
Adult | 1 | 2009 | 15762 | 0.010 |
Why?
|